All are invited to the online Bradford Hill Seminar:

The future of cancer screening: stratified, pan, both or neither?

Professor Peter Sasieni 

King’s Clinical Trials Unit, King’s College London

Register to attend

Register in advance for this free online seminar:

https://phgfoundation.zoom.us/meeting/register/tZYtdOyrqjovEtQkA-Iv94T1fjMaOVTNOsRf

After registering, you will receive a confirmation email containing information about joining the meeting.

Abstract

In this seminar Professor Peter Sasieni will briefly review the current landscape regarding cancer screening. He will then consider the potential for stratifying screening using either polygenic risk scores to differentiate between those with a low, average, or high risk of cancer, or the post-test risk of cancer to offer stratified management. Finally, he will review the potential to expand the scope of cancer screening by adding either new single-site screening programmes or a multi-cancer early detection test. The question of whether a pan-cancer screening test would dissipate the benefit of using polygenic risk scores to stratify screening will also be discussed as will the challenges of reducing screening as risk changes.

About Professor Sasieni

Peter Sasieni is Director of King’s Clinical Trials Unit and Professor of Cancer Prevention at King’s College London. He is the lead statistician and one of the co-lead investigators for the NHS-Galleri Trial evaluating GRAIL’s multi-cancer early detection test for population screening within the NHS and Chair of the National Cancer Research Institute’s Screening, Prevention and Early Diagnosis Group. Sasieni has a PhD in Biostatistics from the University of Washington. He did post-doctoral research in Jack Cuzick’s group at the Imperial Cancer Research Fund (now Cancer Research UK) and was Professor of Biostatistics and Cancer Epidemiology at Queen Mary University of London before moving to King’s.

His research spans: cervical screening and HPV testing, HPV vaccination, evaluating cancer screening programmes, clinical trials in cancer screening and prevention, and statistical methodology. He has a close collaboration with Professor Rebecca Fitzgerald evaluating her Cytosponge-TFF3 test for targeted screening and reducing mortality from oesophageal adenocarcinoma. He sometimes writes for the KCL Cancer Prevention Group blog.

About the Bradford Hill seminars

The Bradford Hill seminar series is the principal series of The Cambridge Population Health Sciences Partnership. This comprises the Departments of Public Health & Primary Care, MRC Biostatistics Unit and MRC Epidemiology Unit at the University of Cambridge, bringing together a multi-disciplinary partnership of academics and public health professionals. The Bradford Hill seminar programme of internationally recognised speakers covers topics of broad interest to our public health research community. It aims to transcend as well as connect the activities of our individual partners.

All are welcome at our Bradford Hill seminars.